Candil Margarita, Zufferey Pascal
Service de rhumatologie, Département de l'appareil locomoteur, CHUV, 1011 Lausanne.
Rev Med Suisse. 2017 Jan 11;13(544-545):105-109.
The anti-IL-6 tocilizumab is a recognized treatment in rheumatoid arthritis and in systemic juvenile idiopathic arthritis. Almost ten years after its first use, there is more information about its security profile and its indication should be extended to other systemic inflammatory diseases, such as the giant cell arteritis. New molecules targetting the IL-6 pathway are under validation : sarilumab, sirukumab and olokizumab. Here is a brief state of the future outlook and trends of this therapeutic class.
抗白细胞介素-6药物托珠单抗是类风湿关节炎和全身型幼年特发性关节炎的一种公认治疗药物。在其首次使用近十年后，关于其安全性的信息更多了，并且其适应证应扩展到其他全身性炎症性疾病，如巨细胞动脉炎。针对白细胞介素-6通路的新分子正在进行验证：沙瑞鲁单抗、司妥昔单抗和奥洛珠单抗。以下是该治疗类别的未来展望和趋势的简要情况。
